Veradermics, Incorporated
MANE
$126.89
$7.526.30%
NYSE
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 85.45% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 29.77% | ||||
| Operating Income | -29.77% | ||||
| Income Before Tax | -24.65% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -24.65% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -24.65% | ||||
| EBIT | -29.77% | ||||
| EBITDA | -- | ||||
| EPS Basic | 96.49% | ||||
| Normalized Basic EPS | 95.88% | ||||
| EPS Diluted | 96.49% | ||||
| Normalized Diluted EPS | 95.88% | ||||
| Average Basic Shares Outstanding | 2,928.02% | ||||
| Average Diluted Shares Outstanding | 2,928.02% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||